Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCT
Saint-Louis, France and Dublin, Ireland – 3rdJune 2025– Priothera Ltd., a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat hematologic malignancies, today announced the appointment of Dr. Hans Menssen, MD, PhD, BBA, to its Board of Directors.
Dr. Menssen most recently served as Senior Global Program Clinical Head at Novartis Oncology, where he led clinical programs across acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), multiple myeloma, chronic myeloid leukemia (CML), myelofibrosis, acute and chronic GvHD, and B-cell malignancies, with a focus on registration-stage development. Over his career, in addition to Novartis, he has held senior roles at Bayer Schering Pharma and Philogen SpA, with a track record of supporting oncology innovation across modalities including small molecules, antibodies, and cell therapies.
' Hans brings deep strategic insight in hematology, clinical development, and regulatory science,' said Florent Gros, Co-Founder and CEO of Priothera. ' His experience across global drug development programs and his understanding of what it takes to bring innovative therapies to patients will make him a valuable voice on our Board as we progress the global Phase 3 MO-TRANS study of mocravimod in AML patients undergoing allo-HCT. We are very pleased to welcome him to the Board.'
A board-certified hematologist and oncologist, Dr. Menssen also holds academic appointments at Charité – University Medicine Berlin in his capacity as assistant professor (Priv-Doz. Dr. med), where he continues to teach and supervise medical research. He has contributed to numerous clinical and translational research efforts throughout his career. He earned his medical degree from the University of Cologne, completed postdoctoral research at the Wistar Institute at the University of Pennsylvania, and holds a Bachelor of Business Administration in health economics from GSBA Zurich in partnership with SUNY (State University of New York).
' I am very pleased to join Priothera's Board at such a key point in its evolution,' said Dr. Hans Menssen. ' Mocravimod represents a promising and differentiated approach to improving outcomesin AML patients undergoing allo-HCT, and I look forward to supporting the team in advancing this important program.'
Priothera's Board of Directors is composed of:
***
About mocravimod
Mocravimod (KRP203) is a synthetic S1P receptor modulator being developed for the adjunctive treatment of AML to enhance the curative potential of allo-HCT. Mocravimod's dual mechanism of action preserves the graft-versus-leukemia (GvL) effect, critical for eliminating cancer cells while reducing the risk of graft-versus-host disease (GvHD), a major complication following allo-HCT. This novel treatment approach – mocravimod being the only S1P receptor modulator in development to treat blood cancers – tackles a high unmet medical need and aims to improve patients' quality of life.
About Priothera
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in combination with cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for hematological malignancies, focusing initially on acute myeloid leukemia (AML), in combination with allogeneic hematopoietic cell transplant (allo-HCT). Mocravimod is currently the only treatment with the potential to reduce transplant side effects of graft-versus-host disease (GvHD) without compromising the graft's anticancer effect against leukemia (Graft-versus-Leukemia, or GvL), thereby enhancing the curative potential of allo-HCT.
Founded in 2020, Priothera operates in France, with headquarters in Dublin. The company is led by a highly experienced management team with deep expertise in hematology, oncology, immunology and cell-based therapies. Priothera is backed by leading international life sciences investors, including Fountain Healthcare Partners, abrdn, EarlyBird Venture Capital, BEI and Bpifrance Grand Est.
For more information please visit www.priothera.com or follow Priothera on LinkedIn www.linkedin.com/company/priothera/
Contacts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Big Comeback: This Big Bank Stock is Outperforming Its Peers
Written by Christopher Liew, CFA at The Motley Fool Canada Canada's banking sector is known globally as a bedrock of stability. The Big Banks, in particular, stand tall to this day despite economic downturns and financial crises. However, Toronto-Dominion Bank (TSX:TD) lost favour with investors last year. The country's second-largest financial institution pleaded guilty to violating the U.S. Bank Secrecy Act and paid a substantial fine of US$3 billion. Fast-forward to 2025, and the $166.6 billion bank looks stronger from the money laundering-related case. As of June 11, 2025, TD outperforms its Big Six peers as well as the broad market. The share price is $95.98, with a commanding year-to-date gain of plus-28.8% and a corresponding dividend yield of 4.4%. What is the reason for the big comeback? Has TD regained investors' confidence? Should you buy this large-cap stock now? TD never lost its handle on profitability despite a tarnished reputation in the financial markets. In Q2 fiscal 2025, net income climbed 334% to $11.1 billion compared to Q2 fiscal 2024. The Wholesale Banking segment reported a record $419 million in net income, a 16% jump compared to the same quarter last year. In the first half of the same fiscal year, the reported net income was $13.9 billion, a 158.3% increase from a year ago. Interestingly, TD's U.S. Retail Bank demonstrated resilience and delivered its sixth quarter of consumer deposit growth and double-digit growth. Raymond Chun, TD Bank Group's new President and CEO, said, 'TD delivered strong results this quarter, with robust trading and fee income in our markets-driven businesses as well as deposit and loan growth in Canadian Personal and Commercial Banking.' 'We are well-positioned as we enter the second half of the year,' he added. U.S. regulators imposed a cap on TD's US retail banking assets. The US$434 billion asset cap forms part of the penalty agreement with the Office of the Comptroller of the Currency (OCC). TD must downsize and comply with specific remedial actions before pursuing growth initiatives. The probationary period is five years. On February 10, 2025, TD announced the sale of its entire 10.1% stake in financial services firm Charles Schwab. Chun said, 'As part of our strategic review, we have been evaluating capital allocation and have made the decision to exit our Schwab investment.' TD intends to use a portion of the US$5.6 billion proceeds for share buybacks. The rest will be invested in businesses to boost performance and accelerate organic growth plans. Moreover, the private transaction provides the Canadian bank with a significant capital boost and liquidity flexibility. TD also realized a significant return on investment. Several factors contributed to TD regaining investors' confidence. First, the core Canadian personal and commercial banking segment delivered better-than-expected but solid revenue growth. Second, there is consistent progress on the Anti-Money Laundering (AML) remediation, according to Chun. Third, the broader positive sentiment in the financial sector, aided by lower interest rates, is another factor for the stock's surprise surge. Last, TD remains well-capitalized and has a sufficient buffer (14.3% CET1 ratio) against potential economic downturns. You can safely say that this Big Bank stock is back on investors' radars in 2025, primarily for income-seeking investors. The post Big Comeback: This Big Bank Stock is Outperforming Its Peers appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Charles Schwab is an advertising partner of Motley Fool Money. Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool recommends Charles Schwab. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
7 hours ago
- Medscape
Immune Modulation in MDS: Our Core Strategies Need to Change
MILAN — Immune-based treatments continue to fall short in myelodysplastic syndromes (MDS). Now, experts from the European Hematology Association's (EHA) Specialized Working Group on MDS here at the EHA 2025 Congress are reevaluating their core strategies, from clinical trial endpoints to patient selection and timing. The researchers are suggesting the need for a shift in how these therapies are developed and deployed, as new data suggests that current benchmarks might be missing meaningful responses and that immune dysfunction in MDS can evolve over time. MDS are a heterogeneous group of clonal myeloid stem and progenitor cell disorders marked by ineffective hematopoiesis, cytopenias, and a risk of progression to acute myeloid leukemia. Immune dysregulation is thought to be a key driver in MDS pathogenesis, raising hopes that modulating immune responses within the bone marrow niche could alter disease trajectory. Yet, despite numerous attempts, immune-based interventions have largely failed to yield meaningful clinical results. Choosing the Right Endpoints Currently, few therapies targeting inflammation and immune activation are approved for MDS — namely antithymocyte globulin, with or without cyclosporine A, lenalidomide, and luspatercept. However, a growing list of investigational agents is under study, including cytokine inhibitors, signaling pathway inhibitors, immune checkpoint inhibitors, bispecific and trispecific antibodies, and chimeric antigen receptor cell-based therapies. Anne Sophie Kubasch, MD Anne Sophie Kubasch, MD, a hematologist at the University Medical Hospital Leipzig, Germany, presented preliminary findings from two trials by the German MDS Study Group: the phase 2 CANFIRE trial of the IL-1Beta inhibitor canakinumab and the LUCAS trial of the IRAK4 inhibitor emavusertib. The CANFIRE trial enrolled 11 patients treated for 6 months, while LUCAS included 36 patients treated for 4 months. Both studies failed to meet their primary endpoint, hematologic improvement in erythroid cells per International Working Group (IWG) 2018 criteria, by the end of the treatment period. Despite this, Kubasch noted that several patients opted to continue treatment due to perceived clinical benefit, such as reduced fatigue or general improvement. Some also showed biomarker changes or delayed hematologic responses. These findings led her to question whether hematologic improvement in erythroid cells is the most appropriate efficacy endpoint for immunomodulatory agents. 'We can argue that current IWG endpoint criteria are too rigid for immune modulation trials,' she said. 'Late or gradual responses may go undetected.' Kubasch suggested that future trials should incorporate patient-reported outcomes and quality-of-life metrics as co-primary endpoints. 'We may focus on composite endpoints combining various parameters, such as hematologic trends, biomarker shifts, molecular remission or stability, and, of course, patient-reported benefits.' Selecting the Right Patients A second key question, Kubasch said, is whether the right patients are being selected for immunotherapy. She cited a recent transcriptomic analysis of bone marrow CD34+ cells from 183 MDS patients that identified two immune subtypes based on the expression of six genes — including IRAK4 , the target of emavusertib. These subtypes were called hyperactive (HIC) and moderate (MIC) immune clusters. The HIC group had greater activation of immune-related pathways and higher infiltration of natural killer cells and M1 macrophages. 'We might be treating the wrong immune subgroup with immunomodulators,' she said, hypothesizing that it's possible that only MIC patients were being enrolled in their trials, contributing to negative results. She proposed a stepwise stratification approach: Baseline assessment (low-risk MDS diagnosis, anemia, transfusion burden) Genetic stratification (cytogenetics, mutations, resistance markers) Immune transcriptomic profiling (HIC/MIC clustering) 'Selective inclusion of patients with immune activation, such as those with an HIC profile, is essential,' she concluded. Targeting the Right Immune Alterations Valeria Santini, MD, associate professor of hematology at the University of Florence Medical School, Italy, focused her remarks on immunosuppressive therapy, a long-used but inconsistently effective strategy in MDS. To re-evaluate its role, Santini reviewed older literature — what she called 'archaeological digging.' She showed that complete responses and survival benefits are achievable in some patients, albeit rarely. Importantly, she emphasized that immune dysfunction in MDS is dynamic. 'It changes during the course of the disease,' she said. Therefore, precise immune profiling at both the subtype and patient level is needed. Optimization of immunosuppressive therapy is hampered by the lack of prospective randomized trials, heterogeneity in study populations, poor characterization of immune abnormalities, and the need for integration with novel agents. 'It is not one cure for all,' she said. 'By selecting patients, we might be more successful than in the past.' Finding the Right Drugs and the Right Timing Lionel Adès, MD, PhD, professor of hematology at Saint-Louis Hospital, Paris, France, commented to Medscape Medical News that, while the biological rationale for immune modulation is strong, clinical evidence remains weak. Lionel Adès, MD, PhD 'Maybe we don't have the right drugs or combinations. Maybe we're using them too late in the disease course,' he said. Immune dysregulation might play a role early in MDS, but by the time patients are treated, it could be too late to alter the disease with immune-targeted agents. Moreover, Adès noted that immune therapies often require extended treatment periods before activity can be detected, while traditional MDS trial endpoints focus on earlier timepoints. 'If a drug appears completely ineffective, it's not ethical to keep a patient on trial for a year just to see if something happens,' he said. Still, he remains cautiously optimistic. He pointed to the EHA-sponsored i4MDS Consortium, which aims to deepen understanding of MDS immunobiology, and to data from the STIMULUS MDS 2 study presented during the session by Amer Zeidan, MBBS, MHS, of Yale University, New Haven, Connecticut. That study evaluated the TIM-3 immune checkpoint inhibitor sabatolimab plus azacitidine as a first-line therapy in MDS. Although the trial failed to show a survival advantage overall, subgroup analysis revealed a benefit among female patients. 'This is something very interesting,' Adès said. 'It's something we didn't look at before, because we never thought survival could differ between male and female MDS patients.' While sabatolimab development has since been discontinued, other agents targeting the same pathway remain in the pipeline. 'This finding could be valuable for stratifying future trials by sex,' he said. Kubasch reported relationships with BMS, Curis, Jazz, Johnson & Johnson, and Novartis. Santini reported serving on advisory boards for AbbVie, Ascentage, BMS, Geron, GSK, Keros, Novartis, Servier, and Takeda. Adès disclosed research support from BMS/Celgene and AbbVie, and advisory roles with AbbVie, Amgen, BMS, Jazz, Novartis, Roche, and Takeda.
Yahoo
9 hours ago
- Yahoo
Johnson & Johnson announces new Phase 1b data on bleximenib
Johnson & Johnson announced new Phase 1b data showing antileukemic activity and a safety profile for bleximenib in combination with venetoclax and azacitidine for the treatment of acute myeloid leukemia harboring KMT2A gene rearrangements or NPM1 gene mutations. The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML. The results were featured in an oral presentation at the 2025 European Hematology Association Congress. Even though AML is the most common type of acute leukemia in adults, it has the lowest survival rate and is associated with poor patient outcomes, despite treatment advances to date – especially for patients with KMT2Ar and NPM1m. The Phase 1b dose-finding study evaluated 125 patients with relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML who harbored KMT2Ar or NPM1m. Bleximenib in combination with VEN + AZA was evaluated across multiple dose levels without step-up dosing. Of the 85 relapsed or refractory patients, 36 percent received one, 42 percent received two and 12 percent received three lines of prior treatment; 47 percent had previously been treated with venetoclax. The bleximenib data at 100 mg twice a day in combination with VEN + AZA showed higher efficacy and a similar safety profile in comparison to other dose levels. At the recommended Phase 2 dose, patients with relapsed or refractory AML achieved an overall response rate of 82 percent and a composite complete response rate of 59 percent. The newly diagnosed, intensive chemo-ineligible patient population showed an ORR of 90 percent and a cCR rate of 75 percent. Safety analysis of the study population showed a profile comparable among dose groups, genetic subtypes and disease settings. At the RP2D in combination with VEN+AZA, differentiation syndrome events were reported in two of 49 patients. Bleximenib safety data continued to support a lack of QTc prolongation signal, with no events of Grade 3 or higher and only three Grade 1 events at the RP2D. The most common all-grade treatment-emergent adverse events were nausea, thrombocytopenia, neutropenia and anemia. The most common Grade 3 or higher TEAEs were thrombocytopenia, neutropenia, and anemia. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on JNJ: Disclaimer & DisclosureReport an Issue RFK Jr. names eight members to vaccine panel, WSJ reports RFK Jr. names new CDC vaccine advisory panel picks, STAT reports Johnson & Johnson reports results from Phase 3b APEX study on TREMFYA Johnson & Johnson Elects Daniel Pinto to Board Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
